Brokerages Set Biogen Inc. (NASDAQ:BIIB) PT at $182.48

Biogen Inc. (NASDAQ:BIIB) has earned an average rating of “Hold” from the twenty-five ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have issued a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $183.08.

Several analysts recently commented on BIIB shares. Jefferies Financial Group increased their target price on shares of Biogen from $190.00 to $210.00 and gave the company a “buy” rating in a research note on Friday, November 28th. Wall Street Zen cut Biogen from a “buy” rating to a “hold” rating in a report on Sunday, November 9th. Weiss Ratings reissued a “hold (c-)” rating on shares of Biogen in a research note on Monday, December 15th. Morgan Stanley boosted their target price on Biogen from $149.00 to $156.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. Finally, Royal Bank Of Canada decreased their price target on Biogen from $217.00 to $210.00 and set an “outperform” rating for the company in a research report on Friday, October 31st.

Biogen Trading Up 2.9%

Shares of BIIB stock opened at $174.80 on Friday. The stock has a 50-day simple moving average of $163.65 and a 200 day simple moving average of $145.29. The stock has a market capitalization of $25.64 billion, a P/E ratio of 15.93, a P/E/G ratio of 1.47 and a beta of 0.13. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $185.17. The company has a quick ratio of 2.04, a current ratio of 2.72 and a debt-to-equity ratio of 0.35.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, topping the consensus estimate of $3.89 by $0.92. Biogen had a net margin of 15.98% and a return on equity of 14.13%. The firm had revenue of $2.53 billion for the quarter, compared to analysts’ expectations of $2.34 billion. During the same period in the previous year, the business earned $4.08 earnings per share. Biogen’s revenue for the quarter was up 2.8% compared to the same quarter last year. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. On average, sell-side analysts expect that Biogen will post 15.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Elevation Point Wealth Partners LLC purchased a new stake in shares of Biogen in the 2nd quarter valued at approximately $25,000. Accredited Wealth Management LLC grew its position in Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 185 shares in the last quarter. Rothschild Investment LLC raised its stake in Biogen by 64.7% during the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 88 shares during the period. Concord Wealth Partners raised its stake in Biogen by 100.0% during the 2nd quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 114 shares during the period. Finally, True Wealth Design LLC lifted its holdings in shares of Biogen by 62.9% in the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 90 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.